Salute e Benessere

Radiopharmaceuticals Market Size To Reach $26.51 Billion By 2031 | CAGR 14.4%…

The radiopharmaceuticals market encompasses a growing number of clinical trials in targeted therapy that are expected to gain prominence in the coming years. The radiopharmaceuticals market encompasses a growing number of clinical trials in targeted therapy that are expected to gain prominence in the coming years. Global radiopharmaceuticals market is recording significant growth owing to the surging incidences of chronic diseases such as lung diseases, cancer, stroke, Alzheimer's,...
PR Newswire
24/10/2024

Biologics Market Size To Reach $1,793.9 Billion By 2031 | CAGR 18.2%: The…

The global biologics market observing significant growth owing to the increasing occurrence of chronic diseases globally and surging preference for outsourcing biologics manufacturing operations. The biologics market entails an array of platforms and services that are expected to dominate the market in the coming years. The report carries out an in-depth analysis of market trends, key players, and future opportunities. The global biologics market observing significant growth owing to the...
PR Newswire
24/10/2024

Pharmaceutical Drying Equipment Market to Hit USD 8.18 Billion by 2029 with 7.1%…

Browse in-depth TOC on "Pharmaceutical Drying Equipment Market" Browse in-depth TOC on "Pharmaceutical Drying Equipment Market" 221 - Tables 52 - Figures 226 - Pages Based on type, the pharmaceutical drying equipment market is segmented into vacuum dryers, spray dryers, freeze dryers, fluidized bed dryers, and other dryers. Among these, in 2023, freeze dryer segment the fastest growing segment in the pharmaceutical drying equipment market. This is due to the increasing...
PR Newswire
24/10/2024

Mölnlycke® Health Care and Transdiagen announce research collaboration to drive…

James Harding, CEO, Transdiagen added "We are thrilled to be working with Mölnlycke on this R&D programme. This collaboration will allow Mölnlycke access to TDG's novel models to generate functional insights regarding the mode of action of innovative and biological wound treatment solutions. We believe this marks a new chapter in the approach to data driven, evidence-based product development for the treatment of complex wounds." James Harding, CEO, Transdiagen added "We are…
PR Newswire
24/10/2024

Shaklee, A Leader in Clean Wellness and Skincare, Expands into Australia

"Our entry into Australia is not just about opening a new market—it represents the beginning of the next era of growth for Shaklee," said Shaklee's Chairman and CEO, Roger Barnett. "We remain committed to our vision of building healthier communities and fostering true wellness around the world." "Our entry intoAustraliais not just about opening a new market—it represents the beginning of the next era of growth for Shaklee," said Shaklee's Chairman and CEO,Roger…
PR Newswire
24/10/2024

Frost & Sullivan Honors Industry Leaders with Prestigious 2024 Best Practices…

"Frost & Sullivan's Best Practices Awards recognize companies that lead the charge in driving growth and innovation," said Jeff Frigstad, Global Senior Vice President of Best Practices at Frost & Sullivan. "These forward-thinking organizations are at the forefront of emerging trends and are shaping the future of their industries. I am thrilled to congratulate our award recipients, whose accomplishments set the bar for excellence and inspire progress across sectors."…
PR Newswire
24/10/2024

EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control…

The new FDA-funded collaboration builds on research performed by EpiVax during two previous FDA contracts that evaluated the immunogenicity risk of generic drug impurities. Under the first contract, EpiVax demonstrated the value of in silico and in vitro methods for immunogenicity risk assessment of two well-known generic peptide drugs. Under the second contract, EpiVax developed the What-if Machine (WhIM), an algorithm designed to perform iterative modifications to the amino acid sequence of a…
PR Newswire
24/10/2024

Philips and Medtronic advocacy partnership aims to help accelerate access to…

Both companies also join the newly established World Stroke Organization Advocacy CoalitionAmsterdam, the Netherlands– Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke care is crucial to saving lives and reducing long-term disability. As leaders in stroke diagnosis and treatment, the two organizations are...
Nasdaq GlobeNewswire
24/10/2024

Coronado Research Limited announce appointment of Professor Jennifer…

Coronado Research CEO, Andrew MacGarvey said "I am delighted to add Jen to the Coronado team. As Chief Scientific Officer, she will ensure that our service offering remains true to our vision. She brings significant experience in novel methodologies, something that is key to evolving clinical trials. Jen will combine high-calibre research with commercial understanding to build out our service offerings to accelerate drug development and ensure new treatments better meet market needs."…
PR Newswire
24/10/2024

IMG Announces 2024 Leave Your Mark Grant Winners

"Mission of Hope is deeply grateful to be a recipient of IMG's Leave Your Mark Grant, which will help us continue to provide vital support and resources to those in need," said Mission of Hope's Chief Operating Officer, Drew Garrison. "This contribution empowers us to expand our impact in Haiti and the Dominican Republic and bring hope to more men, women, and children across the island." "Mission of Hope is deeply grateful to be a recipient of IMG's Leave Your Mark…
PR Newswire
24/10/2024

UPM Biomedicals launches FibGel™ the world's first injectable nanocellulose…

FibGel is customizable owing to its tunable properties that allow adjustable stiffness and the incorporation of additional components. This flexibility enables tailored solutions for varying clinical needs and holds promise in a wide range of medical applications, including soft tissue repair, orthopaedic treatments, aesthetics, drug delivery, and cell transplantation. With FibGel's biological safety evaluations in accordance with ISO 10993, it is an ideal component for companies developing…
PR Newswire
24/10/2024

The Oxford-Harrington Rare Disease Centre (OHC) Announces Inaugural 2024 Rare…

The OHC brings together world-leading research, expertise in therapeutics development and new financial models to advance solutions to critical challenges in rare diseases. The OHC brings together world-leading research, expertise in therapeutics development and new financial models to advance solutions to critical challenges in rare diseases. Each Scholar will receive £100,000 (UK) /$100,000(US andCanada ), personalised therapeutics development support from industry experts to help...
PR Newswire
24/10/2024

Press Release: Dupixent late-breaking positive phase 3 data in chronic…

Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support US regulatory resubmission by year-end; if approved, Dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than 10 yearsMore than 300,000 people in the US suffer from chronic...
Nasdaq GlobeNewswire
24/10/2024

deepc and The AI Centre for Value-Based Healthcare enter partnership to…

The AI4VBH's goal is to speed up and improve diagnosis and care across a large number of care pathways including dementia, heart failure and cancer. Over the past five years, the AI4VBH has developed numerous platforms to provide secure access to high-quality electronic health data for the development of AI models and deployment of AI technology. deepc's partnership with the AI4VBH will be focused on providing technology, resources and expertise to support the continued development of new and…
PR Newswire
24/10/2024

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD)…

BiogenInc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer's Disease (CTAD) annual conference, taking place October 29 - November 1, in Madrid, Spain. The presentations will include updates on new scientific findings from Biogen's Alzheimer's portfolio, highlighting data on different aspects of treatment and data examining preclinical Alzheimer's disease and race. “These data showcase the breadth of our Alzheimer's disease research...
Nasdaq GlobeNewswire
24/10/2024

NTC grants Chinoin the license and distribution rights in Mexico and LatAm for…

The deal represents an important step for the internationalization of such product that was developed to respond to the unmet medical needs to enhance patient compliance. The deal represents an important step for the internationalization of such product that was developed to respond to the unmet medical needs to enhance patient compliance. In fact, bowel preparation before a colonoscopy is currently often experienced as burdensome and, if inadequately performed, it leads to suboptimal...
PR Newswire
24/10/2024

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and…

Mini Oral Presentation DetailsTitle: The A2AR Antagonist Inupadenant Promotes Humoral Responses in Patients Abstract Number: 174MO Session Title: Mini Oral Session 1 Date / Time: December 12, 2024 at 9:24 am CESTTitle: Inupadenant Combined with Chemotherapy in Patients with Non-Squamous NSCLC Progressing On or After Immune Checkpoint Inhibitor Therapy: Results from Dose-Finding Part of the A2A-005 Trial Abstract Number: 120MO Session Title: Mini Oral Session 2 Date / Time: December 12,...
Nasdaq GlobeNewswire
24/10/2024

Curaleaf Report: Online and unregulated cannabis poses serious health risks with…

This is largely being driven by consumers buying illegal cannabis to seek relief from health conditions like chronic pain, insomnia, and anxiety (73% of online purchasers) - many of whom could be eligible for legally prescribed medical cannabis. This is largely being driven by consumers buying illegal cannabis to seek relief from health conditions like chronic pain, insomnia, and anxiety (73% of online purchasers) - many of whom could be eligible for legally prescribed medical cannabis...
PR Newswire
24/10/2024

ITM, TUM, and TUM University Hospital Sign New Framework Agreement to Advance…

Neufahrn / Garching / Munich, Germany, October 24, 2024 –ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, the Technical University of Munich (TUM) and the TUM University Hospital (Klinikum rechts der Isar der Technischen Universität or MRI), today announced a new framework agreement for the research and development of innovative radiopharmaceuticals and radionuclides for the treatment of cancer. This collaboration builds on a long-standing...
Nasdaq GlobeNewswire
24/10/2024

Final Day of Global Health Exhibition Celebrates the Next Generation of Health…

The third day marked the establishment of fresh MoUs, partnerships and deals totalling USD 13.3bn. These included a cooperation agreement between the Saudi State-owned Health Holding Company and Huawei, as well as a partnership agreement between the Council of Health Insurance and the Johns Hopkins Center. The third day marked the establishment of fresh MoUs, partnerships and deals totallingUSD 13.3bn. These included a cooperation agreement between the Saudi State-owned Health Holding...
PR Newswire
24/10/2024

Seegene Holds Partner Executive Roundtable with Microsoft, and Springer Nature…

- Global experts and scientists participated in building a diagnostic product development eco-system utilizing Springer Nature's scientific network - Global experts and scientists participated in building a diagnostic product development eco-system utilizing Springer Nature's scientific network - Companies fostered collaboration to drive collective impact towards next year's 'a world free from diseases' declaration ceremony SEOUL, South Korea , Oct. 24, 2024 /PRNewswire/ --...
PR Newswire
24/10/2024

Vistin Pharma ASA: Invitation to Q3 2024 conference call

Vistin Pharma ASA will release its third quarter and YTD 2024 results on Thursday 31st of October 2024. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Thursday 31 stof October at 08:30 CET. There will be a Q&A session following the management discussion.The conference call will be held in English.The third quarter conference call will be available via web and audio through the following access points: Webcast:...
Nasdaq GlobeNewswire
24/10/2024

Dedicare's Interim Report 1 January - 30 September 2024: Market still…

The period January - September 2024 The period January -September 2024 Performance measures https://mb.cision.com/Public/1178/4055763/b44a625dbdf929ef_org.png Chief Executive Officer's statement "The market was still challenging in the third quarter" "The weaker market for contracted staff that we've encountered in recent quarters also persisted in the third quarter of the year. Net sales and EBITA fell sharply against a strong comparative quarter of the previous...
PR Newswire
24/10/2024

Orexo Interim Report Q3 2024

› Total net revenues of SEK 136.5 m (156.1) › Total net revenues ofSEK 136.5 m(156.1) › EBITDA ofSEK -0.7 m(-9.5) › Net earnings ofSEK -41.9 m(-33.3) › US Commercial segment net revenues ofSEK 131.0 m(140.4), in local currency USD 12.6 m (13.0) › Cash flow from operating activities ofSEK -13.4 m(-21.9), cash and cash equivalents of SEK 114.9 m (184.2) › Earnings per share before and after dilution amounted toSEK -1.21(-0.97) › Orexo AB´s...
PR Newswire
24/10/2024
Altri  Comunicati